Dec 17 (Reuters) - Sanofi and Teva

Pharmaceuticals said on Tuesday that their drug,

duvakitug, met the main goals in a mid-stage trial when tested

in patients with inflammatory bowel disease (IBD).

The drug met the main goals of disease remission and

effectiveness for the treatment of ulcerative colitis and

Crohn's disease, respectively.

These are the two most common forms of IBD, which affects

between 2.4 million and 3.1 million people in the U.S.

U.S.-listed shares of Teva rose nearly 14%, while

U.S.-listed shares of Sanofi climbed 4% premarket.